Please assess the completion status of the following clinical trial:

Trial Title: STerOids in COVID-19 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the trial~* Male or Female, aged 18 years or above~* New onset of symptoms suggestive of COVID-19 e.g. new onset cough and/or fever, and/or loss of smell or taste within 7 or fewer days of participant being seen at visit 1~* In the Investigator's opinion, is able and willing to comply with all trial requirements~Exclusion Criteria:~* A known allergy to investigational medicine product (IMP) (budesonide)~* Any known contraindication to any of the IMPs (budesonide)~* Patient currently prescribed inhaled or systemic corticosteroids~* Recent use, within the previous 7 days of inhaled or systemic corticosteroids~* Patient needs hospitalisation at time of study consent~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.~* Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled budesonide (Type: EXPERIMENTAL): Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
- Standard of care (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).